ArticleInvestigational new drugs2017

Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.

Alexandra Tyulyandina et al.PubMed ↗Publisher ↗

No numbers read from the abstract.